Martina Dameri, Alessandro Garlaschi, Paola Cuccarolo, Andrea Ceccardi, Mario Stabile, Irene Valente, Licia Gristina, Massimo Calabrese, Alberto Ballestrero, Alberto Tagliafico, Gabriele Zoppoli
Multiple myeloma is a hematological cancer characterized by relapse after treatment and poor prognosis. Ixazomib, a second-generation protease inhibitor, is one of the most recently available treatments for relapsed or refractory multiple myeloma, while it has also shown good potential as antitumoral agent in preclinical solid tumor models such as breast cancer cell lines. Here we report the case of a 68-year-old female with multiple myeloma and an incidental cT1b (9 mm) hormone receptor positive breast cancer lesion that showed a complete pathological response to a three-month combination therapy with Ixazomib, bendamustine and dexamethasone and no signs of disease relapse during the later follow-up...
June 2, 2023: Tumori
Yuanshan Yao, Haojie Xuan, Jing Wang, Libao Gong, Wen Gao
BACKGROUND: Esophageal squamous cell carcinoma (ESCC) is one of the most common upper gastrointestinal malignancies worldwide. Tertiary lymphoid structures (TLS) are tumor-infiltrating immune cells aggregates coupled with stromal cells which are similar to secondary lymphoid organs. The objective of this study is to explore the predictive effects of two common genes associated with TLS models on prognosis and immunotherapy effects in ESCC patients. METHODS: Clinical information for ESCC patients in the TCGA(The Cancer Genome Altas) cohort and GSE 53625 were collected...
May 30, 2023: Tumori
Jacob Stein, Hannah E Kay, Jeremy Sites, Afsaneh Pirzadeh, Benny L Joyner, Toni Darville, Marc A Bjurlin, Tracy L Rose, Ilona Jaspers, Matthew I Milowsky
Electronic cigarette, or vaping, product use-associated lung injury (EVALI) is an increasingly recognized entity with the potential for severe pulmonary toxicity. We present the case of a young man first evaluated at a tertiary care center in the United States in 2019 with newly diagnosed testicular cancer with acute respiratory failure, which was initially attributed to possible metastatic disease but eventually determined to be related to EVALI. This case highlights the clinical features of EVALI, the potential diagnostic dilemma that can arise with EVALI when occurring in the setting of malignancy and the importance of inquiring about vaping use among patients with malignancy, especially in adolescents and young adults...
May 10, 2023: Tumori
Olga Nigro, Marta G Podda, Federico Pellegatta, Elisabetta Schiavello, Carlo A Clerici, Igor Catalano, Giovanna Visconti, Marco Albarini, Roberto Luksch, Monica Terenziani, Andrea Ferrari, Michela Casanova, Veronica Biassoni, Cristina Meazza, Filippo Spreafico, Giovanna Gattuso, Giovanna Sironi, Nadia Puma, Luca Bergamaschi, Stefano Chiaravalli, Maura Massimino
OBJECTIVES: Although transfusion support is commonly used in oncological palliative care, there is still a paucity of literature. We examined the transfusion support provided in the terminal stage of the disease and compared the approach at a pediatric oncology unit and a pediatric hospice. CASE DESCRIPTION: This case series analyzed patients treated at the Fondazione IRCCS Istituto Nazionale dei Tumori di Milano (INT)'s pediatric oncology unit who died between January 2018 and April 2022...
May 8, 2023: Tumori
Laure Kornreich, Daniel Orbach, Nayla Nicolas, Hervé J Brisse, Pablo Berlanga, Anne-Sophie Defachelles, Ludovic Mansuy, Cécile Verite, Laure Saumet, Marie Karanian, Nadège Corradini
BACKGROUND: Desmoid-type fibromatosis are rare intermediate tumors in children and adolescents. Owing to local aggressiveness and relapse, systemic treatment for symptomatic advanced or progressive forms is recommended. Following promising results in adult patients, oral vinorelbine is investigated in young patients. METHODS: A retrospective review of young patients (<25 years old) with advanced or progressive desmoid type fibromatosis treated with oral vinorelbine in eight large centers of the Société Française des Cancers de l'Enfant was performed...
April 28, 2023: Tumori
(no author information available yet)
No abstract text is available yet for this article.
April 17, 2023: Tumori
Celeste Cagnazzo, Marco Basiricò, Federica Palermo, Franca Fagioli
Observational trials are crucial to assess the generalizability in the real world of evidence deriving from registration studies. Despite the unquestionable importance of this type of studies, Italian researchers have had to face many obstacles over the years, mainly due to ambiguous definitions and to a complex but at the same time incomplete legislation. The regulatory adjustments to the European Regulation 536/2014 have further complicated the operating and operational framework, making observational research a real "Cinderella" of the Italian system...
April 8, 2023: Tumori
Matteo Silva, Massimo Guglielmi, Carlo Alfredo Clerici, Maura Massimino, Andrea Ferrari
No abstract text is available yet for this article.
March 24, 2023: Tumori
Marta G Podda, Cristina Meazza, Giovanna Gattuso, Giovanna Sironi, Olga Nigro, Luca Bergamaschi, Veronica Biassoni, Michela Casanova, Stefano Chiaravalli, Andrea Ferrari, Roberto Luksch, Nadia Puma, Elisabetta Schiavello, Filippo Spreafico, Paolo Grampa, Siranoush Manoukian, Sabina Vennarini, Paola Collini, Primo A Daolio, Massimiliano Gennaro, Marco Guzzo, Carlo Morosi, Davide Biasoni, Maura Massimino, Monica Terenziani
Each year approximately 35,000 children and adolescents are diagnosed with cancer in Europe. Five-year survival rates have improved and now reach 80% in most European countries, thanks to a combination of chemotherapy, radiotherapy, and surgery. To date, there are more than 44,000 Italians still living several years after being diagnosed with cancer in developmental age. The risk of premature morbidity and mortality for cancer survivors is well known and documented. Approximately 60% of survivors of cancer in childhood and adolescence have at least one chronic health condition in later life, and more than one in four develop severe or life-threatening disorders...
March 24, 2023: Tumori
Antonio Silvani
The purpose of this editorial is to consider some of the aspects of the diagnosis and treatment of adult gliomas. These are rare diseases with all their limitations. Innovations in diagnosis and therapy and their constraints are analyzed and compared with the current treatment reality. Aspects affecting these patients' quality of life are highlighted.
March 24, 2023: Tumori
Samuel Sherng Young Wang
The cancer stem cell model hopes to explain solid tumour carcinogenesis, tumour progression and treatment failure in cancers. However, the cancer stem cell model has led to minimal clinical translation to cancer stem cell biomarkers and targeted therapies in solid tumours. Many reasons underlie the challenges, one being the imperfect understanding of the cancer stem cell model. This review hopes to spur further research into clinically translatable cancer stem cell biomarkers through first defining cancer stem cells and their associated models...
March 24, 2023: Tumori
Dario Zerini, Marco Rotondi, Stefania Volpe, Eleonora Pisa, Emanuele Frigo, Cristiana Pedone, Michele Flospergher, Vincenzo Bagnardi, Samuele Frassoni, Cristiana Iuliana Fodor, Francesca Spada, Nicola Fazio, Daniela Alterio, Barbara Alicja Jereczek-Fossa
BACKGROUND: The impact of radiotherapy (RT) in neuroendocrine neoplasms is still unknown, and outcomes could be improved by a better insight in RT response predictors. This retrospective analysis investigates the potential correlation between Ki-67 and RT response to evaluate its role as biological marker of radiosensitivity. MATERIAL AND METHODS: Data from patients treated at an Italian NET-referral center between 2015 and 2020 were retrieved. Inclusion criteria included: histologically-proven diagnosis of NEN, Ki-67 status, indication (symptomatic and/or ablative) and at least one post-RT radiological assessment...
March 20, 2023: Tumori
Laura Vittoria, Laura Sala, Valeria Summo, Iolanda Capone, Elena Conca, Martina Toma, Joseph Ottolenghi, Francesca Testa, Umberto Cortinovis, Biagio Paolini, Antonello Cabras, Antonella Aiello, Fabio Bozzi
INTRODUCTION: During the last few years it has been shown that an anaplastic T cell lymphoma can develop as a rare and late sequelae of implant-based breast reconstruction. This malignancy was recognized in the 2017 by WHO and named breast implant associated anaplastic large T cell lymphoma (BIA-ALCL). BIA-ALCL usually presents as abundant effusion around the implant, thus, in addition to cytology smears, its diagnosis also requires immunohistochemistry, T cells clonality and cytometry...
March 20, 2023: Tumori
Silvia Calabria, Giulia Ronconi, Letizia Dondi, Carlo Piccinni, Antonella Pedrini, Immacolata Esposito, Alice Addesi, Giuseppe Rossi, Felicetto Ferrara, Adriano Venditti, Nello Martini
OBJECTIVE: To identify newly diagnosed patients with acute myeloid leukemia in 2017 treated with intensive chemotherapy or unfit for intensive chemotherapy, and to assess their probability of receiving allogeneic stem cell transplantation and survival, from the Italian National Health Service perspective. PATIENTS AND METHODS: From the Ricerca e Salute database, adults with an in-hospital diagnosis of acute myeloid leukemia (International Classification of Disease-9th version-Clinical Modification code 205...
March 9, 2023: Tumori
Daniele Carrieri, Fedro Alessandro Peccatori, Giovanni Boniolo
'Oncohumanities' is a new field of oncology and humanities which integrates a rich gamut of humanity disciplines and oncological expertise to tackle patients' real needs and priorities. To promote knowledge and awareness on this topic, we propose a training programme that will blend conceptual knowledge underpinning oncology practice with and person-centred care based on the humanisations of care, on empowerment of patients, and on respect for their diversities. Oncohumanities differs from most existing medical humanities training as it is integrated and engaged with oncology (rather than an add-on)...
March 9, 2023: Tumori
Ugo Pastorino, Giovanni Leuzzi, Federica Sabia, Paolo Girotti, Leonardo Duranti, Stefano Radaelli, Marco Fiore, Silvia Stacchiotti, Giannatempo Patrizia, Roberto Salvioni, Alessandro Gronchi
BACKGROUND: Complex surgical resection and reconstruction for rare thoracic cancers (RTCs) represent a major challenge, given their very low frequency, extreme variability of presentation, multi-modality treatment options and inadequate outcome prediction. We analysed the experience of a tertiary referral centre on a consecutive series of patients with thoracic germ cell tumours, thymomas and sarcomas, with the aim of reporting the long-term outcome by cancer type and complexity of surgical procedures...
February 16, 2023: Tumori
Francesca De Felice, Claudia Marchetti, Maria Serpone, AnnaMaria Camarda, Barbara Vischioni, Rossana Ingargiola, Daniela Musio, Ester Orlandi
PURPOSE: To evaluate the role of upper-neck irradiation versus standard whole-neck irradiation in patients with N0-1 nasopharyngeal carcinoma. METHODS: We conducted a PRISMA guideline based systematic review and meta-analysis. Randomized clinical trials assessing upper-neck irradiation versus whole-neck irradiation with or without chemotherapy in non-metastatic N0-1 nasopharyngeal carcinoma patients were identified. The studies were searched on the PubMed, Embase and Cochrane library up to March 2022...
February 16, 2023: Tumori
Fausto Petrelli, Agostina De Stefani, Ivano Vavassori, Federica Motta, Andrea Luciani, Francesca Trevisan
OBJECTIVE: To evaluate various outcomes of different lengths of androgen deprivation therapy in high- and very-high-risk prostate cancer, we conducted a network meta-analysis of randomized trials. The treatment of high-risk PC comprises the use of radical radiotherapy associated with various durations of androgen deprivation therapy, with luteinizing hormone releasing hormone analogues initiated during or immediately before the beginning of radiation. METHODS AND MATERIALS: This study followed the PRISMA extension statement to report network meta-analyses...
February 9, 2023: Tumori
Irene Donato, Kiran K Velpula, Andrew J Tsung, Jack A Tuszynski, Consolato M Sergi
PURPOSE: Neuroblastoma is a pediatric solid tumor with a prognosis associated with histology and age of the patient, which are the parameters of the well-established current classification (Shimada classification). Despite the development of new treatment options, the prognosis of high-risk neuroblastoma patients is still poor. Therefore, there is a continuous need to stratify the children suffering from this tumor. A mathematical and computational approach is proposed to enable automatic and precise cancer diagnosis on the histological slide...
January 16, 2023: Tumori
Andrea Milani, Valentina Tuninetti, Sandro Pignata, Domenica Lorusso, Daniele Castaldo, Ugo De Giorgi, Antonella Savarese, Nicoletta Biglia, Giuseppa Scandurra, Giorgia Mangili, Massimo Di Maio, Margherita Turinetto, Marco Bellero, Serafina Mammoliti, Silvia Testa, Giulia Scotto, Andrea Purro, Grazia Artioli, Giorgio Valabrega
INTRODUCTION: Low molecular weight heparin (LMWH) has been the backbone of the treatment of cancer associated thrombosis (CAT). Direct-acting oral anticoagulants (DOACs) have shown efficacy and safety not inferior to LMWH and guidelines included DOACs as an option for CAT treatment. Nevertheless, DOACs are still poorly prescribed in patients with cancer. The aim of this survey was to better understand prescription patterns of anticoagulants, in particular of DOACs, especially in gynecological cancers (GCs)...
January 6, 2023: Tumori
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.